Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 119-122

  Goto, Naoki ^a   Yoshimura, Reiji ^a   Kakeda, Shingo ^a   Nishimura, Joji ^a   Moriya, Junji ^a   Hayashi, Kenji ^a   Katsuki, Asuka ^a   Hori, Hikaru ^a   Umene Nakano, Wakako ^a   Ikenouchi Sugita, Atsuko ^a   Korogi, Yukunori ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Creatine; Frontal lobe; Left basal ganglia; Parieto occipital node; Proton magnetic resonance spectroscopy

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CREATINE; GLUTAMIC ACID; GLUTAMINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRONTAL LOBE; GLUTAMATERGIC NERVE CELL; HUMAN; MALE; NERVE CELL; NEUROTRANSMISSION; POSITIVE AND NEGATIVE SYNDROME SCALE; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84930480383     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S25582     Document Type: Article

References (16)

1. Tibbo P, Hanstock C, Allen P. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry. 2004;161:1116-1118.
2. Olbrich HM, Valerius G, Rusch N, et al. Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry. 2008;9:59-63.
3. Bustillo JR, Rowland LM, Mullins P, et al. 1H-MRS at 4 tesla in minimally treated early schizophrenia. Mol Psychiatry. 2010;15:629-636.
4. Reid MA, Stoeckel LE, White DM, et al. Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry. 2010;68:625-633.
5. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
6. Goto N, Yoshimura R, Ueda N, et al. Reduction of brain gammaaminobutylic acid (GABA) concentrations in early-stage schizophrenia patients: 3T proton MRS study. Schizophr Res. 2009;112:192-193.
7. Stanley JA, Williamson PC, Drost DJ, et al. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull. 1996;22:597-609.
8. Ohrmann P, Siegmund A, Suslow T, et al. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naïve and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J Psychiatr Res. 2007;41:625-634.
9. Theberge J, Al-Semaan Y, Williamson PC, et al. Glutamate and glutamine in anterior cinglate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry. 2003;160:2231-2233.
10. Benes FM. Amygdalocortical circuitry in schizophrenia: from circuits to molecules. Neuropsychopharmacology. 2010;35:239-257.
11. De la Fuente-Sandoval C, Favilla R, Alvarado P, et al. Glutamate increase in the associative striatum in schizophrenia: a longitudinal magnetic resonance spectroscopy preliminary study. Gac Med Mex. 2009;145:109-113. Spanish.
12. Goto N, Yoshimura R, Kakeda S, et al. No alteration of brain GABA after 6 months of treatment with atypical antipsychotic drugs in earlystage first-episode schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:1480-1483.
13. Lewis S. Synaptic neurotransmission: a closer look at GABA(B) receptors. Nat Rew. 2010;11:664.
14. Levitt P, Eagleson KL, Powell EM. Regulation of neocortical interneuron development and the implications for neurodevelopmental disorders. Trends Neurosci. 2004;27:400-406.
15. Mescher M, Merkle H, Kirsh J, Garwood M. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 1998;11:266-272.
16. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672-679.